gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Angiotensin II receptor, type 1

angiotensin receptor, angiotensin II receptor
Angiotensin II is a potent vasopressor hormone and a primary regulator of aldosterone secretion. It is an important effector controlling blood pressure and volume in the cardiovascular system. It acts through at least two types of receptors. This gene encodes the type 1 receptor which is thought to mediate the major cardiovascular effects of angiotensin II. This gene may play a role in the generation of reperfusion arrhythmias following restoration of blood flow to ischemic or infarcted myocardium. It was previously thought that a related gene, denoted as AGTR1B, existed; however, it is now believed that there is only one type 1 receptor gene in humans. At least five transcript variants have been described for this gene. Additional variants have been described but their full-length nature has not been determined. The entire coding sequence is contained in the terminal exon and is present in all transcript variants. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Angiotensin II, HAD, Renin, ARB, AGE
Papers on angiotensin receptor
The effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: a meta-analysis of observational studies.
He et al., Shanghai, China. In Pharmacoepidemiol Drug Saf, Feb 2016
PURPOSE: There has been much controversy over the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) on patients with renal dysfunction.
Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.
Raizada et al., Gainesville, United States. In Hypertension, Feb 2016
We conclude that (1) chronic Ang II infusion regulates HSC proliferation, mediated by angiotensin receptor type 1a, (2) Ang II accelerates HSC to myeloid differentiation resulting in accumulation of C-C chemokine receptor type 2(+) HSCs and inflammatory monocytes in the spleen, and (3) Ang II impairs homing and reconstitution potentials of the donor HSCs.
Low-Salt Diet and Circadian Dysfunction Synergize to Induce Angiotensin II-Dependent Hypertension in Mice.
Rudic et al., Lexington, United States. In Hypertension, Feb 2016
In contrast, Period isoform KO mice lost their circadian rhythm in blood pressure on a low-salt diet, because of an increase in resting blood pressure, which was restorable to rhythmicity by the angiotensin receptor blocker losartan.
Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients.
Xu et al., Shanghai, China. In J Clin Hypertens (greenwich), Feb 2016
UNASSIGNED: The authors aimed to investigate the superiority of angiotensin system blockade (angiotensin-converting enzyme [ACE] inhibitor/angiotensin receptor blocker [ARB]) plus a calcium channel blocker (CCB) (A+C) over other combination therapies in antihypertensive treatment.
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Bakris et al., Chicago, United States. In Blood Purif, Feb 2016
Very high albuminuria is a hallmark of diabetic nephropathy with reductions by either angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blocker (ARB) monotherapy associated with slowed nephropathy progression.
Therapy modifications during hospitalization in patients with chronic heart failure.
Lainscak et al., Ljubljana, Slovenia. In Eur J Intern Med, Feb 2016
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists were prescribed to 78%, 58% and 20% of patients on admission and 72%, 65% and 23% at discharge, respectively.
Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
Lacro et al., Boston, United States. In Can J Cardiol, Jan 2016
The primary aims of this report were to examine the evidence related to medical therapy for Marfan syndrome, including recently completed randomized clinical trials on the efficacy of β-blockers and angiotensin II receptor blockers for the prophylactic treatment of aortic enlargement in Marfan syndrome, and to provide recommendations for medical therapy on the basis of available evidence.
Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure.
Marwick et al., Hobart, Australia. In Am J Cardiol, Jan 2016
The significant associations of the combined primary outcome were chronic lung disease, chronic kidney disease, atherosclerotic vascular disease (peripheral, coronary, and cerebrovascular), diabetes, anemia, lower systolic blood pressure, previous admission, multidisciplinary treatment, and use of beta-blockade and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group et al., Hong Kong, Hong Kong. In Jama, Oct 2015
OBJECTIVE: To evaluate the safety and efficacy of different oral doses of the nonsteroidal mineralocorticoid receptor antagonist finerenone, given for 90 days to patients with diabetes and high or very high albuminuria who are receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Cripe et al., Columbus, United States. In Lancet Neurol, Feb 2015
METHODS: In this randomised, double-blind, placebo-controlled trial, boys from three centres in the USA aged 7 years or older with Duchenne muscular dystrophy, myocardial damage by late gadolinium enhancement cardiac MRI and preserved ejection fraction received either eplerenone 25 mg or placebo orally, every other day for the first month and once daily thereafter, in addition to background clinician-directed therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
Intraclass differences among antihypertensive drugs.
Tobe et al., London, Canada. In Annu Rev Pharmacol Toxicol, 2014
The four major classes of antihypertensive drugs—diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers)—have significant qualitative and quantitative differences in the adverse effects they cause.
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
Krum et al., Geelong, Australia. In Cochrane Database Syst Rev, 2014
Beta-adrenergic blocking agents, angiotensin converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) can improve survival and reduce hospital readmissions and are recommended as first-line therapy in the treatment of heart failure.
Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.
Malik et al., Manchester, United Kingdom. In Rev Diabet Stud, 2014
A number of novel potential candidates, including erythropoietin analogues, angiotensin II receptor type 2 antagonists, and sodium channel blockers are currently being evaluated in phase II clinical trials.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
PARADIGM-HF Investigators and Committees et al., Glasgow, United Kingdom. In N Engl J Med, 2014
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction.
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
NAC-MD-01 Study Investigators et al., New Orleans, United States. In Lancet, 2014
We assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension.
Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.
Thekkumkara et al., Amarillo, United States. In Am J Physiol Renal Physiol, 2012
results suggest in proximal tubule epithelial cells,hyperglycemia-induced hAT(1)R downregulation is largely mediated through sodium-glucose cotransporter-dependent glucose influx; glucose-mediated changes in hAT(1)R gene expression may participate in the pathogenesis of diabetic renal disease
AGTR1 gene variation: association with depression and frontotemporal morphology.
Ashley-Koch et al., Durham, United States. In Psychiatry Res, 2012
This study showed that genetic variation in AGTR1 is associated with depression and differences in frontotemporal morphology.
Polymorphisms of angiotensin II type 1 receptor gene and those of angiotensinogen point at culprit artery in ST-segment elevation myocardial infarction.
Stępińska et al., Warsaw, Poland. In Gene, 2012
Polymorphism of AGTR1 1166A/C gene can point at the right coronary artery as infarct-related artery in ST-segment elevation myocardial infarction (STEMI). Polymorphisms of AGT Met235Thr and AGT Thr174Met genes are able to mark increased or reduced odds ratio of circumflex artery as culprit artery in STEMI.
Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells.
Zhang et al., Xi'an, China. In Cell Physiol Biochem, 2011
present study demonstrates that Ang II induces angiogenic factors production partly via AT1/ JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells
AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells.
Falahtpishe et al., Tehrān, Iran. In Pak J Biol Sci, 2011
Data show that angiotensin II through activation of AT1 receptors can stimulate the expression of MMP-2, MMP-13 and VEGF, but not MMP-13, in B16F10 melanoma cells.
share on facebooktweetadd +1mail to friends